Q-omics provides the consensus-scored METTL7B profile across patient tissues and cancer cell-line models. METTL7B expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, METTL7B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, METTL7B RNA expression shows 15,496 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRC, and TGCT as cancer lineages where METTL7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL7B survival associations across molecular data types. METTL7B RNA expression shows survival associations in the most cancer types (31), followed by mutation status (5) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL7B RNA expression–survival associations across cancer types. High METTL7B expression shows unfavorable associations in UVM, LUSC, HNSC and BLCA, but favorable associations in THCA and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for METTL7B RNA expression.
This table summarizes METTL7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for METTL7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL7B shows lower tumor expression in KICH and higher tumor expression in KIRC, THCA, STAD, LUAD and BLCA. The KIRC box plot shows higher METTL7B RNA expression in tumor versus normal tissue (log2 FC = +1.995, t-test p < 0.001).
This table shows molecular features associated with METTL7B in patient tissues and cancer cell lines. In patient samples, METTL7B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, METTL7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
